Santen Pharmaceutical (4536.T) Earnings Analysis

Santen Pharmaceutical (4536.T) next reports earnings on 2026-08-06, consensus EPS 21.27 JPY. Last quarter (2026-02-05) it missed with EPS 24.4 JPY vs 29.29 JPY est (-16.7%). It has beaten estimates in 2/4 recent quarters (50%). Trailing P/E 17.21.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 4536.T next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate21.27 JPY
Revenue estimate70.47B

4536.T earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-02-0524.4 JPY29.29 JPY-16.7%Miss
2025-11-0624.44 JPY20.89 JPY+17%Beat
2025-08-0717.32 JPY23.9 JPY-27.5%Miss
2025-02-0625.33 JPY24.24 JPY+4.5%Beat

Beat rate: 2/4 (50%) over reported quarters with consensus data.

4536.T valuation and analyst view

Trailing P/E17.21
Trailing EPS114.95 JPY
Price / book2.15
Dividend yield1.94%
Market cap639.19B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Santen Pharmaceutical (4536.T)'s next earnings date?

Santen Pharmaceutical is next scheduled to report on 2026-08-06, with a consensus EPS estimate of 21.27 JPY and revenue estimate of 70.47B.

Did 4536.T beat earnings last quarter?

In its 2026-02-05 report, 4536.T posted EPS of 24.4 JPY versus a 29.29 JPY estimate — a miss of 16.7%.

What is 4536.T's earnings track record?

Over the last 4 reported quarters with consensus data, 4536.T beat estimates 2 times (50%).

What is 4536.T's current P/E ratio and EPS?

4536.T trades at a trailing P/E of 17.21 on trailing EPS of 114.94747983188623 JPY.

What do analysts rate 4536.T?

4536.T has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.